Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on ThursdayThe Motley Fool • 04/03/25
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASEPRNewsWire • 04/03/25
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksCNBC • 04/01/25
Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 03/24/25
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Zacks Investment Research • 03/18/25
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKSPRNewsWire • 03/13/25
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in FocusZacks Investment Research • 03/10/25